Cytomegalovirus reactivation after hematopoietic stem cell transplant with CMV‐IG prophylaxis: A monocentric retrospective analysis
- 12 February 2021
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 93 (11), 6292-6300
- https://doi.org/10.1002/jmv.26861
Abstract
Human cytomegalovirus (CMV) represents the most common viral infection after hematopoietic stem cell transplant (HSCT), mainly occurring as reactivation from latency in seropositive patients, with a different prevalence based on the extent and timing of seroconversion in a specific population. Here, we retrospectively analyzed a cohort of patients who underwent HSCT at our Institution between 2013 and 2018, all of whom were prophylactically treated with CMV‐IG (Megalotect Biotest®), to define the incidence and clinical outcomes of CMV reactivation and clinically significant infection. CMV infection occurred in 69% of our patient series, mainly resulting from reactivation, and CMV clinically significant infection (CS‐CMVi) occurred in 48% of prophylactically treated patients. CMV infection and CS‐CMVi impacted neither on relapse incidence nor on overall survival nor on relapse‐free survival. Moreover, a very low incidence of CMV end‐organ disease was documented. CMV‐IG used alone as prophylactic therapy after HSCT does not effectively prevent CMV reactivation.This publication has 42 references indexed in Scilit:
- The pathogenesis of human cytomegalovirusThe Journal of Pathology, 2014
- Donor Cytomegalovirus Status Influences the Outcome of Allogeneic Stem Cell Transplant: A Study by the European Group for Blood and Marrow TransplantationClinical Infectious Diseases, 2014
- Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell TransplantationThe New England Journal of Medicine, 2014
- Primary Prophylaxis of Invasive Fungal Diseases in Allogeneic Stem Cell Transplantation: Revised Recommendations from a Consensus Process by Gruppo Italiano Trapianto Midollo Osseo (GITMO)Transplantation and Cellular Therapy, 2014
- CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMTBlood, 2013
- CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemiaBlood, 2013
- Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patientsBlood, 2011
- Defining the Intensity of Conditioning Regimens: Working DefinitionsTransplantation and Cellular Therapy, 2009
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupClinical Infectious Diseases, 2008
- Circulating Cytomegalovirus (CMV)-Infected Endothelial Cells in Patients with an Active CMV InfectionThe Journal of Infectious Diseases, 1993